Lyell Immunopharma (LYEL) FCF Margin Growth (3y) (2023 - 2026)
Powered by 
Analysis
Lyell Immunopharma (LYEL) FCF Margin Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -1,272.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -2,228.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -5,426.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9,545.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4,612.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -3,088.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 14,060.00 |
| 10 | Lyell Immunopharma | 335.97 Mn | 335.97 Mn | - | -70.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -70.34 Mn |
| Mar 31, 2026 | -186.16 Mn |
| Dec 31, 2025 | -54.25 Mn |
| Sep 30, 2025 | 113.89 Mn |
| Jun 30, 2025 | -43.27 Mn |
| Mar 31, 2025 | -77.51 Mn |
| Dec 31, 2024 | -42.83 Mn |
| Sep 30, 2024 | -10.19 Mn |
| Jun 30, 2024 | -29.19 Mn |
| Mar 31, 2024 | -140.57 Mn |
| Dec 31, 2023 | -31.05 Mn |
| Sep 30, 2023 | -14.83 Mn |